Successful induction treatment of bullous pemphigoid using reslizumab: a case report

Abstract Background Bullous pemphigoid (BP) is a potentially life-threatening autoimmune blistering disease which is characterized by autoantibodies against hemidesmosomal proteins of the skin and mucous membranes. In recent years, the role of eosinophil and immunoglobulin E autoantibodies have been...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hyo-In Rhyou, Song-Hee Han, Young-Hee Nam
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Bullous pemphigoid Reslizumab Eosinophil Corticosteroid Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/d3f44656035f48288734056531971335
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d3f44656035f48288734056531971335
record_format	dspace
spelling	oai:doaj.org-article:d3f44656035f482887340565319713352021-11-21T12:39:18ZSuccessful induction treatment of bullous pemphigoid using reslizumab: a case report10.1186/s13223-021-00619-11710-1492https://doaj.org/article/d3f44656035f482887340565319713352021-11-01T00:00:00Zhttps://doi.org/10.1186/s13223-021-00619-1https://doaj.org/toc/1710-1492Abstract Background Bullous pemphigoid (BP) is a potentially life-threatening autoimmune blistering disease which is characterized by autoantibodies against hemidesmosomal proteins of the skin and mucous membranes. In recent years, the role of eosinophil and immunoglobulin E autoantibodies have been further elucidated in BP, and have been considered potential therapeutic targets. Case presentations A 67-year-old male presented with erythematous bullous eruption. The skin eruption was located on whole body, and suggested BP. Peripheral blood eosinophil count and total immunoglobulin E markedly elevated in initial laboratory findings. Topical and systemic steroid (methylprednisolone 2 mg/kg/day) treatment was started, and his skin symptoms worsened repeatedly, whenever systemic steroid were reduced. On admission day 29, reslizumab (anti-interleukin-5) 3.5 mg/kg was administered intravenously to the patients. The bullous skin lesion began to improve rapidly, and methylprednisolone (8 mg/day) was reduced without any worsening of symptoms during two doses of reslizumab. Conclusions We report a case of successful treatment response to reslizumab administration in a patient with BP. Further studies are needed to confirm the role of anti-interleukin-5 as a treatment for BP in the future.Hyo-In RhyouSong-Hee HanYoung-Hee NamBMCarticleBullous pemphigoidReslizumabEosinophilCorticosteroidImmunologic diseases. AllergyRC581-607ENAllergy, Asthma & Clinical Immunology, Vol 17, Iss 1, Pp 1-4 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Bullous pemphigoid Reslizumab Eosinophil Corticosteroid Immunologic diseases. Allergy RC581-607
spellingShingle	Bullous pemphigoid Reslizumab Eosinophil Corticosteroid Immunologic diseases. Allergy RC581-607 Hyo-In Rhyou Song-Hee Han Young-Hee Nam Successful induction treatment of bullous pemphigoid using reslizumab: a case report
description	Abstract Background Bullous pemphigoid (BP) is a potentially life-threatening autoimmune blistering disease which is characterized by autoantibodies against hemidesmosomal proteins of the skin and mucous membranes. In recent years, the role of eosinophil and immunoglobulin E autoantibodies have been further elucidated in BP, and have been considered potential therapeutic targets. Case presentations A 67-year-old male presented with erythematous bullous eruption. The skin eruption was located on whole body, and suggested BP. Peripheral blood eosinophil count and total immunoglobulin E markedly elevated in initial laboratory findings. Topical and systemic steroid (methylprednisolone 2 mg/kg/day) treatment was started, and his skin symptoms worsened repeatedly, whenever systemic steroid were reduced. On admission day 29, reslizumab (anti-interleukin-5) 3.5 mg/kg was administered intravenously to the patients. The bullous skin lesion began to improve rapidly, and methylprednisolone (8 mg/day) was reduced without any worsening of symptoms during two doses of reslizumab. Conclusions We report a case of successful treatment response to reslizumab administration in a patient with BP. Further studies are needed to confirm the role of anti-interleukin-5 as a treatment for BP in the future.
format	article
author	Hyo-In Rhyou Song-Hee Han Young-Hee Nam
author_facet	Hyo-In Rhyou Song-Hee Han Young-Hee Nam
author_sort	Hyo-In Rhyou
title	Successful induction treatment of bullous pemphigoid using reslizumab: a case report
title_short	Successful induction treatment of bullous pemphigoid using reslizumab: a case report
title_full	Successful induction treatment of bullous pemphigoid using reslizumab: a case report
title_fullStr	Successful induction treatment of bullous pemphigoid using reslizumab: a case report
title_full_unstemmed	Successful induction treatment of bullous pemphigoid using reslizumab: a case report
title_sort	successful induction treatment of bullous pemphigoid using reslizumab: a case report
publisher	BMC
publishDate	2021
url	https://doaj.org/article/d3f44656035f48288734056531971335
work_keys_str_mv	AT hyoinrhyou successfulinductiontreatmentofbullouspemphigoidusingreslizumabacasereport AT songheehan successfulinductiontreatmentofbullouspemphigoidusingreslizumabacasereport AT youngheenam successfulinductiontreatmentofbullouspemphigoidusingreslizumabacasereport
_version_	1718418916606214144

Successful induction treatment of bullous pemphigoid using reslizumab: a case report

Ejemplares similares